Kimura H, Yamaguchi T, Nishino K, Nakagawa M, Yokota S, Nishikawa H, Ito M, Ogura T
Department of Internal Medicine, Toneyama National Hospital, Osaka, Japan.
Nihon Kokyuki Gakkai Zasshi. 1998 Feb;36(2):128-32.
The present study was a retrospective analysis of serum neuron-specific enolase (NSE) assayed in 302 patients with non-small cell lung cancer (NSCLC) before treatment. Serum NSE ranged from 0.6 to 183.0 ng/ml, with a mean value of 12.2 ng/ml, and exceeded 10 ng/ml in 145 patients (48.0%). The mean levels and rate of NSE positivity in 177 patients whose tumors were categorized as small, medium and large (from the product of the maximum and perpendicular axis of the tumor on chest X-ray), were highest in the large group. There was no significant relationship between serum NSE and the response rate to anticancer chemotherapy. The survival period of the patients with elevated serum NSE (median, 5.7 months) was significantly shorter, than those with normal serum NSE levels (median, 12.1 months). Serum NSE is of prognostic significance in a multivariate analysis (p < 0.01), but not predictive of response to chemotherapy in NSCLC.
本研究是对302例非小细胞肺癌（NSCLC）患者治疗前血清神经元特异性烯醇化酶（NSE）进行的回顾性分析。血清NSE范围为0.6至183.0 ng/ml，平均值为12.2 ng/ml，145例患者（48.0%）超过10 ng/ml。177例肿瘤根据胸部X线片上肿瘤最大径与垂直径乘积分为小、中、大三类的患者中，NSE的平均水平和阳性率在大肿瘤组最高。血清NSE与抗癌化疗的缓解率之间无显著关系。血清NSE升高的患者生存期（中位数5.7个月）明显短于血清NSE水平正常的患者（中位数12.1个月）。血清NSE在多因素分析中具有预后意义（p<0.01），但不能预测NSCLC患者对化疗的反应。
